ISSUE 3, MAY 2021 INNOVATION EXPRESS A QUARTERLY PUBLICATION FROM INNOVATIVE HEALTHCARE INSTITUTE INNOVATIVE STRATEGIES TO REDUCE MEDICATION ERRORS DRUG INFORMATION AND COVID-19: A TRAINING OPPORTUNITY IN DISGUISE TIME’S TOP YOUNG INNOVATOR TO SPEAK AT AHIS2021 – GITANJALI RAO ISSUE 3, MAY 2021 TABLE OF CONTENTS CLICK HERE TO SUBSCRIBE AND RECEIVE VIA EMAIL The Future of Crowdsourcing for Biomedical 3 Innovation Express Research is a publication of Heather Centorbi the Innovative Healthcare Institute Drug Information and COVID-19: A Training 4 in Cincinnati, OH. Opportunity in Disguise To receive new Ahmed Abdeldayem issues of the magazine, please How Innovative Drug Development Will Help 5 register for a free subscription. Save Lives Heather Centorbi STAFF Reducing Medication Harms: Thoughts and 6 Editor in Chief Strategies Valerie Clark Ineˆs Ribeiro-Vaz and Renato Ferreira-da-Silva Editorial Assistant Benefits of Remote Patient Monitoring in 9 Heather Centorbi Urban Areas Heather Centorbi Please send inquiries to: info@innovativehci.com Industry News: Advancing Healthcare Through 10 Innovation Summit AHIS 2021 Registration Information 11 TIME's Top Young Innovator to Speak at 12 AHIS 2021 - Gitanjali Rao Heather Centorbi Calendar of Events 13 ISSUE 3, MAY 2021 THE FUTURE OF CROWDSOURCING FOR BIOMEDICAL RESEARCH Heather Centorbi Crowdsourcing is defined as using a large CoronaBio is a digital system that uses crowd to obtain information related to a crowdsourcing to collect real-world data specific task or project. It has long been from people with COVID-19 for use in artificial used by large companies including LEGO, intelligence (AI) technologies to help inform Waze, and Amazon, and is slowly making its healthcare systems about the pandemic and way into the medical industry. what it so come. Patients use this self- reporting tool to choose from pre-fixed A recent article entitled “CoronaBio: Using options related to their symptoms, Crowdsourcing for Biomedical Research on treatments, and observations. There is also COVID-19 to Manage a Pandemic,” written by an e-consent form that allows for data Zisis Kozlakidis and colleagues, was sharing. This new digital tool helps to connect published in Innovations in Digital Health, the community with physicians and Diagnostics, and Biomarkers (IDDB). researchers in a safe and secure way, which Kozlakidis et al states that crowdsourcing be can positively impact the course of any used to inform responses to global health future pandemic. problems. Advancements in technology have transformed what can be achieved If and when another pandemic arrives, a through collective intelligence allowing digital system like CoronaBio will allow for a complex, global issues like the COVID-19 jumpstart on providing valuable and pandemic to be addressed quickly. important information to healthcare system. In addition to collective intelligence, a connected technology infrastructure is vital in managing disease breakouts effectively, enhancing communication, improving safety, and reducing medical errors. With recent advancements in technology, this has become possible. Accumulating and analyzing these data can be done through a new approach Kozlakidis et al call “CoronaBio”. ADVANCEMENTS IN TECHNOLOGY HAVE TRANSFORMED WHAT CAN BE ACHIEVED THROUGH COLLECTIVE INTELLIGENCE. ISSUE 3, MAY 2021 DRUG INFORMATION AND COVID-19: A TRAINING OPPORTUNITY IN DISGUISE Ahmed Abdeldayem, R.Ph., BCPS, CPHQ In August 1962, the first drug information center launched its services at the University of Kentucky Medical Center (Lexington, Kentucky, USA) with a main goal of providing drug. information to physicians, dentists, and nursing staff in addition to providing education to healthcare practitioners. Since then, the scope of pharmacy practice has expanded with a growing need for high-quality, evidence-based information to support the full spectrum of pharmaceutical care. Accordingly, drug information training has evolved to include literature review and analysis skills. During the current coronavirus disease (COVID-19) pandemic, the need for reliable information has never been more important, which puts the abilities of drug information specialists into real testing. Due to the scarcity of evidence, questions about the appropriate therapy for patients with COVID-19 had to be approached with extreme caution since the proposed therapies have not been confirmed for either efficacy or safety. Treatment decisions had to be taken on a case-by- case basis to consider patient comorbidities and to avoid adverse drug reactions and potential interactions. In addition, the abilities of drug information specialists as literature review experts are needed to support formulary management activities through reviewing and analyzing the rapidly emerging evidence. Moreover, awareness about relevant sources of regulatory and safety information was critical to support informed leadership decisions. Almost all professional and regulatory bodies have assigned dedicated resources for guiding pharmacy professionals to the recommended best practices. As professional educators, drug information specialists have faced a major challenge to fulfill their obligations due to social distancing requirements. Therefore, it became essential to utilize virtual meetings to compensate for the banned physical gatherings. Additionally, psychological impact of the crises presented another barrier for the effectiveness of continuous education activities. That is why the utilization of game-based learning, i.e. gamification, provided an acceptable alternative learning methodology. The New England Journal of Medicine (NEJM) launched a learning platform for training practitioners on how to treat patients with COVID-19 using simulated scenarios. Despite the perceived negative impacts of COVID-19 on life and healthcare systems, the pandemic opened the door for drug information specialists to show their qualities in several ways: • Providing patient-specific therapeutic recommendations • Participation in formulary management activities • Utilization of innovative education and training modalities For these reasons, COVID-19 has provided an ideal training opportunity for several aspects of drug information practice. ISSUE 3, MAY 2021 HOW INNOVATIVE DRUG DEVELOPMENT WILL HELP SAVE LIVES Heather Centorbi The development of the COVID-19 which helps to speed up the drug vaccines in less than 1 year has not development process. The drug been seen before. It has and will development process is expensive, but change the course of future drug cost can be reduced when companies development not only in the timespan work together. A collaborative effort is drugs are being created but the way key to quicker and more cost-effective they are developed through drug development. technological advances. Slow adoption rates to drug development The COVID-19 vaccine was sped along innovations are a barrier that will still by regulatory fast-tracking but also need to be overcome. One challenge because of how quick medical trials may include workforces that may not be were completed. Due to remote trained in holding successful virtual trials. technology, these medical trials were Learning how to analyze and compile held almost exclusively online, allowing virtual data is much different than the in- for more participation and for person trials they have come to know involvement to happen more quickly and understand. Other challenges and more often than in-person medical include cultural barriers around adopting trials. Virtual trials are also more easily innovations and negative perceptions of to recruit for and launch. Additionally, pharmaceutical companies’ approach to medical centers have been forced to innovation. Thanks to the COVID-19 advance and adopt virtual technologies pandemic, a collaborative effort between to allow for virtual medical trials to pharma, academia, and payers is slowly continue. becoming the norm. It is also important to note that Fast and reliable drug development will pharmaceutical companies are now continue to grow, and this is an working together rather than against important step forward in the each other, technology-driven world we live in today. ISSUE 3, MAY 2021 REDUCING MEDICATION HARMS: THOUGHTS AND STRATEGIES Ineŝ Ribeiro-Vaz[1–3] and Renato Ferreira-da-Silva[1, 2] 1 Porto Pharmacovigilance Centre, Faculty of Medicine, University of Porto, Porto, Portugal 2 CINTESIS – Center for Health Technology and Services Research, Porto, Portugal 3 Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Porto, Portugal In 1960, Alphonse Chapanis turned his attention from engineering to healthcare. He dedicated himself to studying medication errors, having identified seven sources of errors with potential harm to the patient, including medicine omitted, or given to the wrong patient, at the wrong dose, as an unintended extra dose, by the wrong route, at the wrong time, or as the wrong drug entirely. [1] Sixty years later, many of these errors are still often detected in clinical practice. Drug safety is not a static concept. Over the years, the (wrong) perception that medicines were safe when made available to the population has changed, causing some therapeutic catastrophes, like the thalidomide tragedy in the 1960s. Damage caused by medication can be considered as the “dark side” of drug therapy. Whenever a medicines, when these are under the control decision is made to use medications for a of healthcare professionals or patients. particular patient, it is intended that the These incidents can be related to benefit outweigh the inherent risk. For that, it professional practices, to the products is necessary to be aware of all types of harm themselves or to the processes, and include that can be inflicted on patients, so that failures in prescription, communication, strategies can be adopted to minimize it. This labelling, packaging, denomination, editorial will focus on three strategies for (1) preparation, distribution, dispensing, medication errors, (2) adverse drug administration, education, monitoring, and reactions (ADR), and (3) look-alike-sound- use of medicines.[2] In other words, a alike (LASA) medicines. medication error will be any preventable incident that occurs by action or omission at Medication errors are defined as any any stage of the medication use process preventable incident that can cause harm to and that may or may not cause harm to the the patient or lead to inappropriate use of patient. Reprinted from the Global Journal on Quality and Safety in Healthcare. ISSUE 3, MAY 2021 The definition of error contains the following Other pharmacoepidemiologic data have two important aspects to highlight: the first is suggested, for example, that in United States its avoidable character, which implies the hospitals the incidence of serious and fatal need to implement prevention strategies; the ADRs was relevant, with evaluations of 6.7 second is that not all errors cause harm to and 0.32%, respectively, making ADR between the patient.[3] It is, therefore, essential that the fourth and sixth leading causes of death. health institutions maintain a culture of [7] In the European Union, ADRs represent safety that is not punitive, that allows keeping approximately 6.5% of hospitalizations and updated records of errors, and implementing 197,000 deaths per year.[8] strategies for their minimization. Although some ADRs are unpredictable, such The work performed by Al Mardawi et al.[4] as like penicillin anaphylaxis, many are published in the present issue of Global preventable with adequate foresight and Journal on Quality and Safety in Healthcare monitoring. Preventability usually refers to suggests an abbreviated root cause analysis when the drug treatment plan is inconsistent to reduce preventable harm events due to with current evidence-based practice or is medication errors. This approach, which is unrealistic when taking known circumstances less time-consuming than the traditional root into account.[9] cause analysis, significantly reduced medication error recurrence. However, as a There are two generic approaches that can limitation, authors only applied their be taken to avoid medication harms, as approach to medication errors that caused follows: less serious harm and excluded errors due to 1. Identify subgroups of patients susceptible human cause alone, which limits to developing ADRs and modify the generalizability of the concept. prescribed therapy. 2. Ensure the treatment plan mitigates any ADRs are very important and responsible for possible adverse effects. a significant burden in healthcare services. An ADR is a harmful effect suspected to be caused by a drug,[5] as it is assumed that it is an inherent risk of drug utilization. Even so, some ADRs are preventable, and healthcare providers should be aware of potential harm to patients. Some authors have suggested that ADRs are responsible for approximately 5 to 10% of hospitalizations worldwide, being frequently predictable and possibly avoidable reactions. Furthermore, it has been shown that approximately 25% of the ambulatory patients suffer from ADRs, 13% of which are reported as serious.[6] Reprinted from the Global Journal on Quality and Safety in Healthcare. ISSUE 3, MAY 2021 Prior knowledge of the patient's clinical incomplete knowledge of drug names, newly condition can provide information about available products, and the failure of their susceptibilities and thus reduce the risk manufactures and regulatory authorities to of future ADRs. A patient's medication history recognize the potential for error and to will identify any previous ADRs and therefore conduct rigorous risk assessments. In preclude re-exposure to the drug. New areas addition, manufacturers and regulatory like pharmacogenetics have allowed the authorities do not always recognize the development of new personalized potential for inherent error. Large therapeutic strategies, considering investments are not always available to susceptibilities by population subgroups, and conduct rigorous risk assessments, both for even individual ones. No doubt that a set of commercial brands and for the international new tools with high scientific robustness are nonproprietary name (INN), before the changing the way that ADRs are predicted, designations are approved.[11] The World prevented, detected, and managed. Error Health Organization has also devoted itself to prevention can be planned by means of this problem—through the International retroactive and proactive tools; however, it is Nonproprietary Names Expert Group—to necessary to consider, the approaches used develop INN for pharmaceutical medicinal to detect errors are likely to be different in substances for worldwide acceptance. research and routine care, given the However, there are still many cases where available resources. drugs of the same brand name are marketed in different countries, with different The existence of confusing drug names is active substances. one of the most common causes of medication error and is of concern Health professionals and organizations must worldwide. The first LASA list was published in always bear in mind the fundamental 1973 by Teplitsky,[10] constituting the first principle of healthcare, primum non nocere. major alert to this problem of medication Patient safety and well-being must be the errors. first goal in every setting to build safer systems, learn from errors, and reduce the Contributing to this confusion are human and financial burden. orthography/illegible handwriting, similar packaging or labelling, dosage forms, "THE EXISTENCE OF CONFUSING DRUG NAMES IS ONE OF THE MOST COMMON CAUSES OF MEDICATION ERROR." Reprinted from the Global Journal on Quality and Safety in Healthcare. Download the full article online at doi.org/10.36401/JQSH-20-X8. ISSUE 3, MAY 2021 BENEFITS OF REMOTE PATIENT MONITORING IN URBAN AREAS Heather Centorbi Due to COVID-19, remote patient monitoring has increasingly become more popular and is paving a way to become the new normal. The Center for Connected Health Policy defines remote patient monitoring as “the use of digital technology to collect medical and other forms of health data from individuals in one location and electronically transmit that information securely to healthcare provider in a different location for To utilize remote patient monitoring, they assessment and recommendations”. are often sent home with wearable tools that track the information that needs to Healthcare providers are seeing be collected. Items a patient may be decreased costs, an increase in sent home with include a scale or blood efficiency, and ease of access to patient pressure gauge that connect to a data. Benefits for remote patients, smartphone and sends the information especially those in urban areas, include to the healthcare provide over Wi-Fi. It easier access to healthcare providers, also helps in the area of medication. improved quality of care and improved Patients wear a patch that detects when support. It is a great alternative to having their medication is taken and can be to come into a healthcare facility tracked by the healthcare provider. especially when a stay is not required. Using a remote patient monitoring Remote patient monitoring allows the system allows for more immediate healthcare provider to collect information answers and immediate care. It also such as weight, blood pressure, blood eliminates the need for multiple in- sugar, heart rate, electrocardiograms person visits. Remote patient monitoring and more. The information collected is is changing the future and we are sure to transmitted electronically to the see more wearable technology available healthcare provider and allows them to to track even more health information. monitor the patient remotely. ISSUE 3, MAY 2021 INDUSTRY NEWS: ADVANCING HEALTHCARE THROUGH INNOVATION SUMMIT Topics that will be showcased at The Abstracts Advancing Healthcare Innovation Summit Interested in submitting an abstract or (AHIS): speaking at the event? Please submit your abstract online or request to speak before Personalized Medicine May 31, 2021. There will be two awards for Virtual reality abstracts: Best Abstract Award for AHIS 2021 Healthcare Delivery Models and Best Award for Student Projects. First Digital Health place winners for each category will Artificial Intelligence receive: their names and poster title printed Innovation in Research Methods in our magazine, a recognition certificate, Healthcare Finance access to all journals and free admission to And many more topics… a future conference (total prize value is more than $300). Second and third place September 17-18, 2021 winners will receive a recognition certificate. This extraordinary event is co-hosted by the While there is no cost for submissions, University of Cincinnati Cancer Center and the registration to the event is required. This is Innovative Healthcare Institute, a US-based an excellent way to meet local students, organization with a strong network of vendors and companies in your field and internationally renowned experts who focus on possibly get your work published in our advancing innovative ways to improve human journals. health and the delivery of healthcare. Speakers Location Please apply to be a speaker and share AHIS2021 will be a hybrid online and in-person your expert experience with our audience event based in Cincinnati, Ohio. The two-day on: Summit will be conveniently located in the center of the Innovation District and held at The How academic institutions teach and Graduate Cincinnati Hotel (151 Goodman Drive, educate future innovators Cincinnati Ohio 45219). How various organizations nurture and promote innovations Benefits Roles of various stakeholders in The Advancing Healthcare Innovation Summit is promoting innovations a unique opportunity for healthcare professionals, leaders, policy makers, inventors, Registration investors, consumers, students, and any Registration includes access to all session individual or entity interested in the future of forums and more. Questions? healthcare. Attendees will be able to network, Please contact events@innovativehci.com. exchange knowledge, entice disruptive ideas and cooperate to bring monumental changes Visit the event website here. that improve health, healthcare provision and reduce disparities. ISSUE 3, MAY 2021 AHIS 2021 Advancing Healthcare Innovation Summit Confirmed Speakers Dr. Zisis Kozlakidis, Head of Laboratory Services and Registration is Biobanking at the International Agency for Research on Now Open Cancer Gitanjali Rao September 17-18, 2021 Women in STEM Innovation District Cincinnati, Ohio Tim Schroeder, CEO and Founder of CTI Provide a platform for stakeholders in Peeyush Shrivastava, healthcare innovation to network, CEO of Genetesis exchange knowledge and ideas, and Register by May 31 collaborate to bring monumental for Early Bird pricing changes that improve access to quality healthcare and reduce disparities. Register here. ISSUE 3, MAY 2021 TIME’S TOP YOUNG INNOVATOR TO SPEAK AT AHIS2021 – GITANJALI RAO The Advancing Healthcare Innovation Summit (AHIS) will take place September 17-18, 2021 as a virtual event and in-person event at the Graduate Hotel in Cincinnati, Ohio. AHIS speakers will focus on a variety of topics including: How academic institutions teach and educate future innovators How various organizations nurture and promote innovations Roles of various stakeholders in promoting innovations Surviving innovations: Impact of innovation on workforce Translation of innovation into reality Innovations in conducting research We are excited to announce that Gitanjali In her sessions, she shares her own Rao will be special guest speaker at process of innovation that can be used AHIS2021 - Gitanjali Rao was recognized as by students all over the world. She is an America's Top Young Scientist and received experienced TED speaker and often an EPA Presidential award for inventing her presents in global and corporate forums device, "Tethys"—an early lead detection on innovation and the importance of tool. Gitanjali is also the inventor of "Epione," STEM. a device for early diagnosis of prescription opioid addiction using genetic engineering, Registration is currently open for and "Kindly," an anti-cyberbullying service AHIS2021 here. using artificial intelligence and natural language processing. Students, professionals, and post- docs are invited to submit an Recently, Gitanjali was honored as Forbes abstract by May 31, 2021 here. "30 Under 30 in Science" in 2019 and TIME's "Top Young Innovator" and "Kid of the Year" in 2020 for her innovations and STEM If you are interested in speaking at workshops that she conducts globally, which AHIS2021, please submit this form by has inspired over 38,000 students in the last May 31, 2021. 2 years across four continents. Pharmacoeconomics Principles and Best Practices: A Practical Guide CALENDAR OF UPCOMING EVENTS June 3 ICPTTHM Register here August 9-13 HIMSS 2021 Register here This Guide is a collaborative effort among multidisciplinary experts from different healthcare sectors. The Guide tackles many practical issues related to pharmacoeconomics that are of great importance to healthcare providers, policy and September 17-18 decision makers, and healthcare leaders. We AHIS 2021 hope the readers will find the Guide beneficial. Register here Available for purchase on Amazon. October 11-12 Subscribe Medical Innovation Click here to subscribe to Innovation Summit Express! We will not spam you or sell Register here your information.
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-